|
Basiliximab
resources
DRUG INFO
Basiliximab
Drug Name:
Basiliximab
|
|
|
Indication: For prophylactic treatment of kidney transplant rejection
Pharmacology: Simulect functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.
Mechanism Of Action: Simulect binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.
Drug Category: Immunosupressants; Immunomodulatory Agents; unclassified therapeutic agents (92:00.00)
Brand Names/Synonyms: Ig gamma-1 chain C region; chimeric mouse-human antiCD25; Simulect (Novartis Pharmaceuticals)
Dosage Forms: POWDER FOR SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Chimeric murine/human anti-CD25 antibody
Chemical Formula: C6378H9844N1698O1997S48 >1MIM:L Anti-CD25 antibody light CHIMERIC chain 1 >1MIM:H Anti-CD25 antibody heavy CHIMERIC chain 2 >1MIM:L Anti-CD25 antibody light CHIMERIC chain 2
Half Life: 7.2 +/- 3.2 days (adults)
Drug Type: Approved Drug
# Accession No: BIOD00073
CAS Registry Number: 152923-56-3
| | |
